Nanotechnology Strategies To Advance Outcomes in Clinical Cancer Care
Source abstract
Abstract
Ongoing research into the application of nanotechnology for cancer treatment and diagnosis has demonstrated its advantages within contemporary oncology as well as its intrinsic limitations. The National Cancer Institute publishes the Cancer Nanotechnology Plan every 5 years since 2005. The most recent iteration helped codify the ongoing basic and translational efforts of the field and displayed its breadth with several evolving areas. From merely a technological perspective, this field has seen tremendous growth and success. However, an incomplete understanding of human cancer biology persists relative to the application of nanoscale materials within contemporary oncology. As such, this review presents several evolving areas in cancer nanotechnology in order to identify key clinical and biological challenges that need to be addressed to improve patient outcomes. From this clinical perspective, a sampling of the nano-enabled solutions attempting to overcome barriers faced by traditional therapeutics and diagnostics in the clinical setting are discussed. Finally, a strategic outlook of the future is discussed to highlight the need for next-generation cancer nanotechnology tools designed to address critical gaps in clinical cancer care.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · 3D Printing in Biomedical Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States
Department of Radiology and Molecular Pharmacology Program, Sloan Kettering Institute for Cancer Research, New York, New York 10065, United States
Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri 63108, United States
Division of NanoMedicine, Department of Medicine, and California NanoSystems Institute, University of California, Los Angeles, California 90095, United States
Department of Radiology and Molecular Imaging Program at Stanford (MIPS), Stanford School of Medicine, Stanford, California 94305, United States
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
Department of Materials Science and Engineering, Cornell University, Ithaca, New York 14843, United States
Department of Surgery, Emory University School of Medicine, Atlanta, Georgia 30322, United States
Funding
National Cancer Institute
References (100+)
Show source-provided references
1. 10.1002/btm2.1000310.1002/btm2.10003 ↗
2. Nanotechnology - recruiting, not yet recruiting, available, active, not recruiting studies;ClinicalTrials.gov website,https://clinicaltrials.gov/ct2/results?term=nanoparticle&cond=Cancer&Search=Apply&recrs=b&recrs=a&recrs=d&recrs=c&age_v=&gndr=&type=&rslt=(accessed October 20, 2017) .
3. 10.1038/nrc.2016.10810.1038/nrc.2016.108 ↗
4. 10.1021/acs.accounts.6b0062910.1021/acs.accounts.6b00629 ↗
5. 10.1021/acsnano.7b0485510.1021/acsnano.7b04855 ↗
6. 10.1007/s40265-015-0453-310.1007/s40265-015-0453-3 ↗
7. 10.1038/nmat377610.1038/nmat3776 ↗
8. 10.1073/pnas.130956611010.1073/pnas.1309566110 ↗
9. 10.1021/acs.chemmater.5b0122210.1021/acs.chemmater.5b01222 ↗
10. 10.1586/14737140.2015.108664710.1586/14737140.2015.1086647 ↗
11. 10.3322/caac.2119910.3322/caac.21199 ↗
12. 10.1016/j.jconrel.2016.04.02810.1016/j.jconrel.2016.04.028 ↗
13. 10.1016/j.xphs.2017.06.01910.1016/j.xphs.2017.06.019 ↗
14. 10.1038/nrc.2017.9310.1038/nrc.2017.93 ↗
15. 10.1158/1078-0432.CCR-16-319310.1158/1078-0432.CCR-16-3193 ↗
16. 10.1038/nnano.2017.4710.1038/nnano.2017.47 ↗
17. 10.1016/S0140-6736(14)61457-410.1016/S0140-6736(14)61457-4 ↗
18. 10.1158/0008-5472.CAN-13-278710.1158/0008-5472.CAN-13-2787 ↗
19. 10.1007/s11095-010-0214-710.1007/s11095-010-0214-7 ↗
20. Cancer Nanotechnology Plan 2015;Hartshorn, C., Ed.National Cancer Institute:Rockville, MD, 2016, https://www.cancer.gov/sites/ocnr/research/plan.
21. 10.1186/s12916-016-0623-510.1186/s12916-016-0623-5 ↗
22. 10.1038/nrclinonc.2016.2510.1038/nrclinonc.2016.25 ↗
23. 10.1126/science.aaa817210.1126/science.aaa8172 ↗
24. 10.2217/imt-2017-002410.2217/imt-2017-0024 ↗
25. Checkpoint inhibitors - recruiting, not yet recruiting, available, active, not recruiting studies;ClinicalTrials.gov website,https://clinicaltrials.gov/ct2/results?cond=Cancer&term=checkpoint+inhibitors&cntry1=&state1=&Search=Search&recrs=a&recrs=b&recrs=c&recrs=d(accessed October 20, 2017) .
26. 10.1038/icb.2016.12810.1038/icb.2016.128 ↗
27. Rosenberg S. A. · Cancer Treat. Rep. · 1984 · 68 · 233
28. 10.1038/nrclinonc.2014.17410.1038/nrclinonc.2014.174 ↗
29. CAR T-cell - recruiting, not yet recruiting, available, active, not recruiting studies;ClinicalTrials.gov website,https://clinicaltrials.gov/ct2/results?cond=Cancer&term=CAR+T-cell&cntry1=&state1=&Search=Search&recrs=a&recrs=b&recrs=c&recrs=d(accessed October 20, 2017) .
30. 10.1016/j.semcancer.2017.02.01010.1016/j.semcancer.2017.02.010 ↗
31. 10.1021/nn506202910.1021/nn5062029 ↗
32. 10.1038/nm.219810.1038/nm.2198 ↗
33. 10.1038/nature2327010.1038/nature23270 ↗
34. 10.1016/j.omtn.2017.06.00610.1016/j.omtn.2017.06.006 ↗
35. 10.1038/nature2140510.1038/nature21405 ↗
36. 10.1097/PAP.000000000000016110.1097/PAP.0000000000000161 ↗
37. 10.1056/NEJM19881222319252710.1056/NEJM198812223192527 ↗
38. Lu Y.-C. W. · J. Immunol. · 2017 · 198 · 126.1410.4049/jimmunol.198.Supp.126.14 ↗
39. 10.1038/ni.368210.1038/ni.3682 ↗
40. 10.3389/fimmu.2013.0019010.3389/fimmu.2013.00190 ↗
41. 10.1038/nrc.2017.1710.1038/nrc.2017.17 ↗
42. 10.2217/imt-2017-005710.2217/imt-2017-0057 ↗
43. 10.1038/nrc225010.1038/nrc2250 ↗
44. 10.1158/1078-0432.CCR-11-321610.1158/1078-0432.CCR-11-3216 ↗
45. 10.1038/ncomms1249910.1038/ncomms12499 ↗
46. 10.1056/NEJMoa160495810.1056/NEJMoa1604958 ↗
47. 10.1038/nnano.2017.11310.1038/nnano.2017.113 ↗
48. 10.1016/j.pharmthera.2017.03.00810.1016/j.pharmthera.2017.03.008 ↗
49. 10.1177/153537021664712310.1177/1535370216647123 ↗
50. 10.1016/j.canlet.2016.05.02510.1016/j.canlet.2016.05.025 ↗
51. 10.1016/j.cell.2017.01.01710.1016/j.cell.2017.01.017 ↗
52. 10.1038/nrd.2015.1610.1038/nrd.2015.16 ↗
53. 10.1158/0008-5472.CAN-15-170710.1158/0008-5472.CAN-15-1707 ↗
54. 10.1158/1078-0432.CCR-14-093310.1158/1078-0432.CCR-14-0933 ↗
55. 10.1038/nm.316110.1038/nm.3161 ↗
56. 10.1073/pnas.151520211210.1073/pnas.1515202112 ↗
57. 10.1038/nm.247210.1038/nm.2472 ↗
58. 10.1021/nl803405h10.1021/nl803405h ↗
59. 10.1039/C2IB20174G10.1039/C2IB20174G ↗
60. 10.1172/JCI4560010.1172/JCI45600 ↗
61. 10.1038/nm.272110.1038/nm.2721 ↗
62. 10.1002/wnan.138010.1002/wnan.1380 ↗
63. 10.1126/scitranslmed.300952410.1126/scitranslmed.3009524 ↗
64. 10.1002/bjs.971310.1002/bjs.9713 ↗
65. 10.1007/978-1-60761-609-2_710.1007/978-1-60761-609-2_7 ↗
66. 10.1016/j.jconrel.2014.05.00210.1016/j.jconrel.2014.05.002 ↗
67. 10.1016/j.addr.2015.10.01910.1016/j.addr.2015.10.019 ↗
68. 10.1016/j.bmc.2015.09.05010.1016/j.bmc.2015.09.050 ↗
69. 10.1038/natrevmats.2017.1410.1038/natrevmats.2017.14 ↗
70. 10.1038/nchem.192010.1038/nchem.1920 ↗
71. 10.1038/nchem.48010.1038/nchem.480 ↗
72. 10.2967/jnumed.115.15525910.2967/jnumed.115.155259 ↗
73. 10.1158/1078-0432.CCR-14-317610.1158/1078-0432.CCR-14-3176 ↗
74. 10.1038/srep1475910.1038/srep14759 ↗
75. 10.1021/ja408182p10.1021/ja408182p ↗
76. 10.1021/ja510147n10.1021/ja510147n ↗
77. 10.1016/S0169-409X(99)00059-910.1016/S0169-409X(99)00059-9 ↗
78. Gangloff A. · J. Nucl. Med. · 2005 · 46 · 1866
79. 10.1073/pnas.121454711010.1073/pnas.1214547110 ↗
80. 10.1038/nnano.2016.16410.1038/nnano.2016.164 ↗
81. 10.1021/acsnano.6b0223110.1021/acsnano.6b02231 ↗
82. Chang Y.-J. · Anticancer Res. · 2007 · 27 · 2217
83. 10.1021/mp400054e10.1021/mp400054e ↗
84. 10.1038/nnano.2007.38710.1038/nnano.2007.387 ↗
85. 10.1021/acsnano.6b0767310.1021/acsnano.6b07673 ↗
86. 10.1038/nrclinonc.2010.13910.1038/nrclinonc.2010.139 ↗
87. 10.1146/annurev-chembioeng-061010-11430010.1146/annurev-chembioeng-061010-114300 ↗
88. 10.1038/natrevmats.2016.1410.1038/natrevmats.2016.14 ↗
89. 10.1038/nmat378010.1038/nmat3780 ↗
90. 10.1038/bjc.2013.41510.1038/bjc.2013.415 ↗
91. 10.1021/acsnano.5b0128810.1021/acsnano.5b01288 ↗
92. 10.1016/j.ccr.2009.10.01310.1016/j.ccr.2009.10.013 ↗
93. 10.1016/j.addr.2013.08.00410.1016/j.addr.2013.08.004 ↗
94. 10.1007/s11523-015-0414-510.1007/s11523-015-0414-5 ↗
95. 10.1186/1479-5876-12-1310.1186/1479-5876-12-13 ↗
96. 10.1602/neurorx.2.1.310.1602/neurorx.2.1.3 ↗
97. 10.1016/j.nbd.2009.07.03010.1016/j.nbd.2009.07.030 ↗
98. 10.1016/j.addr.2011.11.01010.1016/j.addr.2011.11.010 ↗
99. 10.1038/nrd.2015.2110.1038/nrd.2015.21 ↗
100. 10.1146/annurev-pharmtox-010814-12485210.1146/annurev-pharmtox-010814-124852 ↗